Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

Active, not recruiting

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2021-12-09

Last Posted Date: 2024-07-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 160

Registration Number: NCT05151640

Locations: 🇧🇬
Acibadem CityClinic UMBAL Tokuda Hospital, Sofia, Bulgaria
🇧🇬
UMBAL Alexandrovska, Sofia, Bulgaria
🇧🇬
MBAL VMA Military Medical Academy, Sofia, Bulgaria

and more 30 locations

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin/linagliptin

First Posted Date: 2021-11-23

Last Posted Date: 2024-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1053

Registration Number: NCT05130463

Locations: 🇰🇷
Cheonan Chungmu Hospital, Cheonan-si, Chungcheongnam-do, Korea, Republic of
🇰🇷
Yeosu Jeil Hospital, Yeosu-si, Jeollanam-do, Korea, Republic of
🇰🇷
Gyeongsang National Univ. Changwon Hospital, Changwon-si, Gyeongsangnam-do, Korea, Republic of

and more 27 locations

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Stiolto Respimat
Device: Trelegy Ellipta
Drug: Furoate/Umeclidinium/Vilanterol
Drug: Tiotropium Bromide/Olodaterol

First Posted Date: 2021-11-19

Last Posted Date: 2023-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11316

Registration Number: NCT05127304

Locations: 🇺🇸
Optum, Eden Prairie, Minnesota, United States

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Conditions: Solid Tumors

First Posted Date: 2021-11-04

Last Posted Date: 2022-11-08

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT05107193

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Phase 2

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: BI 1358894
Drug: Placebo

First Posted Date: 2021-11-02

Last Posted Date: 2024-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 318

Registration Number: NCT05103657

Locations: 🇺🇸
Behavioral Research Specialists, LLC, Glendale, California, United States
🇺🇸
ASCLEPES Research Centers, P.C. dba Alliance Research, Long Beach, California, United States
🇺🇸
CalNeuro Research Group Inc., Los Angeles, California, United States

and more 58 locations

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Withdrawn

Conditions: Diabetes Mellitus, Type 2
Cardiovascular Diseases

Interventions: Drug: empagliflozin
Drug: sulfonylurea
Drug: metformin

First Posted Date: 2021-11-01

Last Posted Date: 2022-06-01

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT05102071

Locations: 🇺🇸
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Phase 1

Completed

Conditions: Gastrointestinal Cancer, Metastatic

Interventions: Drug: BI 905711
Drug: FOLFIRI
Drug: Bevacizumab

First Posted Date: 2021-10-21

Last Posted Date: 2024-01-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT05087992

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan
🇧🇪
UZ Leuven, Leuven, Belgium

and more 2 locations

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FDC 12.5mg empagliflozin/850mg metformin
Drug: Empagliflozin
Drug: Glifage®

First Posted Date: 2021-10-19

Last Posted Date: 2023-07-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT05083949

Locations: 🇧🇷
Instituto de Ciências Farmacêuticas de Estudos e Pesquisas - ICF, Goiânia, Brazil

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 3006337

First Posted Date: 2021-10-13

Last Posted Date: 2023-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT05076422

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
🇳🇱
ICON, Groningen, Netherlands

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 765080

First Posted Date: 2021-10-13

Last Posted Date: 2024-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05075772

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy